Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management · Journal article
The International Journal of Medical Science and Health Research · August 16, 2026
Well-designed and adequately powered for the question it asks.
This systematic review synthesises high-quality evidence that semaglutide 2.4 mg weekly produces reproducible, clinically significant improvements across multiple metabolic diseases including cardiovascular events (20–24% MACE reduction), kidney disease (24% major events reduction, 20% mortality reduction), hepatic histology (62.9% steatohepatitis resolution), and functional capacity, with benefit extending beyond weight reduction. The consistency of benefit across 15 outcome domains and >180,000 participants, combined with low risk of bias and high GRADE certainty for most domains, supports semaglutide as a disease-modifying agent for obesity and its complications.
Systematic review of randomized controlled trials and observational cohort studies. 27 primary studies (24 RCTs, 3 observational cohorts) encompassing >180,000 participants. Eligible populations included adults with obesity or obesity-related metabolic diseases across 15 outcome domains: T2DM, prediabetes, ASCVD, HFpEF, CKD, MASH, and PAD.. Intervention: Semaglutide (long-acting glucagon-like peptide-1 receptor agonist), primarily 2.4 mg weekly; studies included intravenous and oral formulations.. Compared with: Placebo or standard care in included RCTs and observational cohorts..
Semaglutide 2.4 mg weekly produced mean weight reductions of –14.9% to –16.0% versus –2.4% to –5.7% with placebo (all P<0.001) In prediabetes, 84.1–89.8% reverted to normoglycaemia versus 47.8–70.4% with placebo (P<0.0001) SELECT demonstrated 20% MACE reduction (HR 0.80; P<0.001) in obesity without diabetes
Reversibility of benefit upon discontinuation noted but long-term durability and optimal treatment duration not addressed. FLOW demonstrated 24% reduction in major kidney disease events (HR 0.76; P=0.0003) and 20% all-cause mortality reduction (HR 0.80; P=0.01)
Clinicians should consider semaglutide 2.4 mg weekly as first-line therapy in patients with obesity complicated by cardiovascular, renal, or hepatic disease, given consistent benefit across hard endpoints (MACE, mortality, kidney disease progression, hepatic histology) that extends beyond weight reduction. Treatment should be regarded as chronic, with awareness that benefits reverse upon discontinuation and gastrointestinal adverse events occur in most patients but are predominantly mild-to-moderate.
Systematic review of 27 RCTs and observational studies (>180,000 participants) with high GRADE certainty for 11 domains, demonstrating consistent semaglutide benefit across hard endpoints (MACE, mortality, kidney disease, hepatic histology) with low risk of bias in 20/24 RCTs, though industry sponsorship and population representation limit generalizability.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider semaglutide 2.4 mg weekly as first-line therapy in patients with obesity complicated by cardiovascular, renal, or hepatic disease, given consistent benefit across hard endpoints (MACE, mortality, kidney disease progression, hepatic histology) that extends beyond weight reduction. Treatment should be regarded as chronic, with awareness that benefits reverse upon discontinuation and gastrointestinal adverse events occur in most patients but are predominantly mild-to-moderate.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction: Obesity constitutes the pathophysiological hub of interconnected metabolic diseases including type 2 diabetes mellitus (T2DM), atherosclerotic cardiovascular disease (ASCVD), heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), metabolic dysfunction-associated steatohepatitis (MASH) and peripheral artery disease (PAD). Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been evaluated across all these domains. This systematic review synthesised primary evidence on semaglutide across multiple metabolic diseases to determine consistency of benefit across organ systems. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs comprised randomized controlled trials and observational studies evaluating semaglutide in obesity or obesity-related metabolic disease. Systematic reviews were excluded from primary tabulation but retained as contextual comparators. Two reviewers independently screened, extracted data and appraised risk of bias using Cochrane RoB 2 and ROBINS-I; certainty was graded with GRADE. Synthesis was narrative and semi-quantitative by outcome domain. Results: Twenty-seven primary studies (24 RCTs, 3 observational cohorts) encompassing >180,000 participants across 15 outcome domains were included. Semaglutide 2.4 mg weekly produced mean weight reductions of -14.9% to -16.0% versus -2.4% to -5.7% with placebo (all P<0.001). In prediabetes, 84.1-89.8% reverted to normoglycaemia versus 47.8-70.4% (P<0.0001). SELECT demonstrated 20% MACE reduction (HR 0.80; P<0.001) in obesity without diabetes; SOUL demonstrated 14% MACE reduction with oral semaglutide (HR 0.86; P=0.006). FLOW demonstrated 24% reduction in major kidney disease events (HR 0.76; P=0.0003) and 20% all-cause mortality reduction (HR 0.80; P=0.01). STEP-HFpEF demonstrated 7.5-point KCCQ-CSS improvement (P<0.0001). ESSENCE demonstrated steatohepatitis resolution in 62.9% versus 34.3% (P<0.001). STRIDE demonstrated walking distance improvement (ETR 1.13; P=0.0004). C-reactive protein fell 39-48%. Gastrointestinal adverse events occurred in 63.5-84.1% but were predominantly mild-to-moderate and transient, with permanent discontinuation in ~4-5%. Risk of bias was low for 20/24 RCTs; GRADE certainty was high for 11 domains. Discussion: Semaglutide demonstrates reproducible benefit extending beyond weight reduction into hard cardiovascular, renal, hepatic and functional outcomes. Mediation analyses attributed little treatment effect to weight change, implying direct vascular, anti-inflammatory and haemodynamic mechanisms. Benefit was largely independent of baseline BMI, HbA1c and comorbidity severity. Principal limitations include industry sponsorship, under-representation of non-White populations, and reversibility of benefit upon discontinuation. Conclusion: Semaglutide is a disease-modifying agent for the cardiovascular-kidney-metabolic syndrome. Treatment produced significant improvements in body weight, glycaemia, lipids, inflammation, MACE, heart failure, kidney disease, hepatic histology, functional capacity and all-cause mortality, with acceptable safety profile. It is recommended that semaglutide be positioned as first-line therapy in obesity with cardiovascular, renal or hepatic disease; that treatment be regarded as chronic; and that future research prioritise head-to-head incretin comparisons, non-industry-funded trials, and under-represented populations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.